Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.62 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19566656 | 1.00 | CYP11B2 (0.62) | CYP11B2CHRNB2CHRNA4CHRNA7MEN1 | |
| Hydrochloric Acid SCHEMBL2091699 | 0.98 | CYP11B2 (0.61) | CYP11B2CHRNB2CHRNA4CHRNA7MEN1 | |
| SCHEMBL3933755 | 0.91 | CYP11B2 (0.66) | CYP11B2CHRNB2CHRNA4CHRNA7MEN1 | |
| SCHEMBL16410916 | 0.91 | CYP11B2 (0.66) | CYP11B2CHRNB2CHRNA4CHRNA7MEN1 | |
| SCHEMBL30676152 | 0.89 | CYP11B2 (0.67) | CYP11B2CHRNB2CHRNA4CHRNA7MEN1 | |
| SCHEMBL533875 | 0.89 | CYP11B2 (0.67) | CYP11B2CHRNB2CHRNA4CHRNA7MEN1 | |
| Hydrochloric Acid SCHEMBL7507547 | 0.87 | CYP11B2 (0.65) | CYP11B2CHRNB2CHRNA4CHRNA7MEN1 | |
| Hydrochloric Acid SCHEMBL4006926 | 0.87 | CYP11B2 (0.65) | CYP11B2CHRNB2CHRNA4CHRNA7MEN1 | |
| SCHEMBL7897285 | 0.85 | CYP11B2 (0.60) | CYP11B2CHRNB2CHRNA4CHRNA7MEN1 | |
| SCHEMBL30098549 | 0.85 | CYP11B2 (0.60) | CYP11B2CHRNB2CHRNA4CHRNA7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101155783-B | pyrazole compound | HOFFMANN LA ROCHE | 2012-01-04 | — | — | CN | claimed |
| EP-1928840-B1 | 1H-Pyrazole-4-carboxamides, their preparation and their use as 11-beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | claimed |
| EP-1928840-A1 | 1H-PYRAZOLE 4-CARBOXYLAMIDES, THEIR PREPARATION AND THEIR USE AS 11BETA-HYDROXYSTEROID DEHYDROGENASE | F. Hoffmann-Roche AG (CH) | 2008-06-11 | — | — | EP | claimed |
| CN-101155783-A | Pyrazoles | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | CN | claimed |
| US-7345058-B2 | (1-Methyl-5-phenyl-1H-pyrazol-4-yl)-(trans-octahydro-isoquinolin-2-yl)methanone; 11 beta -hydroxysteroid dehydrogenase inhibitor; upregulation of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase); antidiabetic agent; type II diabetes mellitus and metabolic syndrome | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | claimed |
| WO-2006106052-A1 | PYRAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | claimed |
| US-20060223852-A1 | Pyrazoles | GILLESPIE PAUL | 2006-10-05 | — | — | US | claimed |
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4146220-B1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250388574-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12319691-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-12252489-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2025-03-18 | — | — | US | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| US-5824690-A | TREATING ASTHMA, COUGH | HOECHST MARION ROUSSEL INC. (US) | 1998-10-20 | — | — | US | disclosed |
| US-5622966-A | BACTERICIDES TREATING INFECTIONS | WARNER-LAMBERT COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5446044-A | Bactericides | WARNER-LAMBERT COMPANY (US) | 1995-08-29 | — | — | US | disclosed |
| US-5384407-A | Pyrrolidine compounds | WARNER-LAMBERT COMPANY (US) | 1995-01-24 | — | — | US | disclosed |
| US-5342844-A | 7-substituted quinolones and naphthyridones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1994-08-30 | — | — | US | disclosed |
| WO-1993016077-A1 | 7-SUBSTITUTED QUINOLONES AND NAPHTHYRIDONES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-08-19 | — | — | WO | disclosed |
| US-5221676-A | 7-substituted quinolones and naphthyridones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1993-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223852-A1 | Pyrazoles | GPR119, PDK2, PC | CYP11B2 5/4885CHRNB2 4030/4885CHRNA4 4394/4885 |
| US-12252489-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | CYP11B2 1296/4885CHRNB2 36/4885CHRNA4 263/4885 |
| US-12319691-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | CYP11B2 1242/4885CHRNB2 43/4885CHRNA4 249/4885 |
| US-20250388574-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FCER2, HAVCR2 | CYP11B2 1457/4885CHRNB2 24/4885CHRNA4 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.